Primary ovarian insufficiency in the adolescent

Current Opinion in Obstetrics and Gynecology

Volumn 25, Issue 5, 2013, Pages 375-381

  Baker, Valerie L ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

adolescence; anti Mullerian hormone; childhood cancer; fragile X premutation; primary ovarian insufficiency

Indexed keywords

ESTRADIOL; FRAGILE X MENTAL RETARDATION PROTEIN; GONADOTROPIN; MUELLERIAN INHIBITING FACTOR; STEROID 21 MONOOXYGENASE;

ADOLESCENT DISEASE; AUTOSOMAL RECESSIVE DISORDER; CHEMOTHERAPY; CHROMOSOME ABERRATION; CRYOPRESERVATION; EARLY DIAGNOSIS; GALACTOSEMIA; GONADAL DYSGENESIS; HASHIMOTO DISEASE; HORMONAL THERAPY; HUMAN; HYPOPARATHYROIDISM; ISOCHROMOSOME X; KARYOTYPE; MENSTRUAL IRREGULARITY; OOCYTE; OVARIECTOMY; PARENT COUNSELING; PATIENT COUNSELING; PERSONALIZED MEDICINE; PREMATURE OVARIAN FAILURE; PRIMARY AMENORRHEA; PRIORITY JOURNAL; REPRODUCTIVE PROCEDURE; REVIEW; TURNER SYNDROME;

ADOLESCENT; AMENORRHEA; ANTI-MULLERIAN HORMONE; BIOLOGICAL MARKERS; EARLY DIAGNOSIS; ESTROGEN REPLACEMENT THERAPY; FEMALE; FERTILITY PRESERVATION; FRAGILE X MENTAL RETARDATION PROTEIN; GENETIC COUNSELING; GONADOTROPINS; HUMANS; INFERTILITY, FEMALE; KARYOTYPING; PREGNANCY; PRIMARY OVARIAN INSUFFICIENCY; RISK FACTORS; STEROID 21-HYDROXYLASE;

EID: 84884867650     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0b013e328364ed2a     Document Type: Review

References (50)

1. Juul A, Hagen CP, Aksglaede L, et al. Endocrine evaluation of reproductive function in girls during infancy, childhood and adolescence. Endocr Dev 2012; 22:24-39. This publication provides an overview of the ovarian development and the changes in reproductive hormones of girls during infancy, childhood, and adolescence.
2. Rigon F, De Sanctis V, Bernasconi S, et al. Menstrual pattern and menstrual disorders among adolescents: an update of the Italian data. Ital J Pediatr 2012; 38:38.
3. ACOG Committee on Adolescent Healthcare. ACOG Committee Opinion No. 349 November 2006: Menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Obstet Gynecol 2006; 108:1323-1328.
4. Pinola P, Lashen H, Bloigu A, et al. Menstrual disorders in adolescence: a marker for hyperandrogenaemia and increased metabolic risks in later life? Finnish general population-based birth cohort study. Hum Reprod 2012; 27:3279-3286.
5. Hagen CP, Main KM, Kjaergaard S, et al. Inhibin B and estradiol levels in Turner syndrome depend on age and karyotype: longitudinal study of 70 Turner girls with or without spontaneous puberty. Hum Reprod 2010; 25:3134-3141.
6. Nelson SM. Biomarkers of ovarian response: current and future applications. Fertil Steril 2013; 99:963-969.
7. Pawelczak M, Kenigsberg L, Milla S, et al. Elevated serum anti-Mullerian hormone in adolescents with polycystic ovary syndrome: relationship to ultrasound features. J Pediatr Endocrinol Metab 2012; 25:983-989.
8. Hagen CP, Aksglaede L, Sorensen K, et al. Individual serum levels of anti-Mullerian hormone in healthy girls persist through childhood and adolescence: a longitudinal cohort study. Hum Reprod 2012; 27:861-866. This study reports the natural longitudinal course of circulating AMH levels from childhood to adolescence among girls enrolled in the Copenhagen Puberty Study.
9. Lie Fong S, Visser JA, Welt CK, et al. Serum anti-Mullerian hormone levels in healthy females: a nomogram ranging from infancy to adulthood. J Clin Endocrinol Metab 2012; 97:4650-4655. This is one of the few studies that addresses the problem of limited normative data available for AMH over the female lifespan.
10. Hagen CP, Aksglaede L, Sorensen K, et al. Serum levels of anti-Mullerian hormone as a marker of ovarian function in 926 healthy females from birth to adulthood and in 172 Turner syndrome patients. J Clin Endocrinol Metab 2010; 95:5003-5010.
11. Zhong Q, Layman LC. Genetic considerations in the patient with Turner syndrome -45,X with or without mosaicism. Fertil Steril 2012; 98:775-779. This article provides an overview of the genetic variants of Turner syndrome.
12. Trolle C, Hjerrild B, Cleemann L, et al. Sex hormone replacement in Turner syndrome. Endocrine 2012; 41:200-219.
13. Gonzalez L, Witchel SF. The patient with Turner syndrome: puberty and medical management concerns. Fertil Steril 2012; 98:780-786.
14. Bakalov VK, Gutin L, Cheng CM, et al. Autoimmune disorders in women with Turner syndrome and women with karyotypically normal primary ovarian insufficiency. J Autoimmun 2012; 38:315-321. This study confirms that autoimmune disorders are more common with Turner syndrome compared with 46 XX POI.
15. Gould HN, Bakalov VK, Tankersley C, Bondy CA. High levels of education and employment among women with Turner syndrome. J Womens Health 2013; 22:230-235.
16. De Caro JJ, Dominguez C, Sherman SL. Reproductive health of adolescent girls who carry the FMR1 premutation: expected phenotype based on current knowledge of fragile X-associated primary ovarian insufficiency. Ann N Y Acad Sci 2008; 1135:99-111. (Pubitemid 351862142)
17. Allen EG, Sullivan AK, Marcus M, et al. Examination of reproductive aging milestones among women who carry the FMR1 premutation. Hum Reprod 2007; 22:2142-2152. (Pubitemid 47241859)
18. Wehbe RM, Spiridigliozzi GA, Heise EM, et al. When to tell and test for genetic carrier status: perspectives of adolescents and young adults from fragile X families. Am J Med Genet A 2009; 149A:1190-1199.
19. Dillon KE, Gracia CR. Pediatric and young adult patients and oncofertility. Curr Treat Options Oncol 2012; 13:161-173. This review highlights the recent data about the effect of cancer treatments on reproductive potential and options for fertility preservation.
20. Metzger ML, Meacham LR, Patterson B, et al. Female reproductive health after childhood, adolescent, and young adult cancers: guidelines for the assessment and management of female reproductive complications. J Clin Oncol 2013; 31:1239-1247. This review summarizes the task force recommendation for reproductive complications in girls treated for childhood, adolescent, and young adult cancers.
21. Green DM, Kawashima T, Stovall M, et al. Fertility of female survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol 2009; 27:2677-2685.
22. Thomas-Teinturier C, El Fayech C, Oberlin O, et al. Age at menopause and its influencing factors in a cohort of survivors of childhood cancer: earlier but rarely premature. Hum Reprod 2013; 28:488-495.
23. Hamre H, Kiserud CE, Ruud E, et al. Gonadal function and parenthood 20 years after treatment for childhood lymphoma: a cross-sectional study. Pediatr Blood Cancer 2012; 59:271-277.
24. Signorello LB, Mulvihill JJ, Green DM, et al. Congenital anomalies in the children of cancer survivors: a report from the childhood cancer survivor study. J Clin Oncol 2012; 30:239-245. The authors reported no increase in congential anomalies among the children of cancer survivors.
25. Brougham MF, Crofton PM, Johnson EJ, et al. Anti-Mullerian hormone is a marker of gonadotoxicity in pre and postpubertal girls treated for cancer: a prospective study. J Clin Endocrinol Metab 2012; 97:2059-2067. This is one of the few studies which have prospectively evaluated AMH measurements as a marker of gonadotoxicity in children undergoing cancer treatment.
26. Dillon KE, Sammel MD, Prewitt M, et al. Pretreatment anti-Mullerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy. Fertil Steril 2013; 99:477-483. This is one of the few studies examining the acute effects of cancer therapy on prepubertal adolescents and young women.
27. Berry GT. Galactosemia and amenorrhea in the adolescent. Ann N Y Acad Sci 2008; 1135:112-117; This is the only report summarizing the data regarding POI associated with galactosemia. (Pubitemid 351862150)
28. Persani L, Rossetti R, Cacciatore C. Genes involved in human premature ovarian failure. J Mol Endocrinol 2010; 45:257-279.
29. Perry JR, Corre T, Esko T, et al. A genome-wide association study of early menopause and the combined impact of identified variants. Hum Mol Genet 2013; 22:1465-1472.
30. Latronico AC, Arnhold IJ. Gonadotropin resistance. Endocr Dev 2013; 24:25-32.
31. Kallio S, Aittomaki K, Piltonen T, et al. Anti-Mullerian hormone as a predictor of follicular reserve in ovarian insufficiency: special emphasis on FSH-resistant ovaries. Hum Reprod 2012; 27:854-860.
32. Little DT, Ward HR. Premature ovarian failure 3 years after menarche in a 16-year-old girl following human papillomavirus vaccination. BMJ Case Rep 2012.
33. Covington SN, Hillard PJ, SterlingEW, Nelson LM. A family systems approach to primary ovarian insufficiency. J Pediatr Adolesc Gynecol 2011; 24:137-141.
34. Bidet M, Bachelot A, Bissauge E, et al. Resumption of ovarian function and pregnancies in 358 patients with premature ovarian failure. J Clin Endocrinol Metab 2011; 96:3864-3872.
35. Van Kasteren YM, Schoemaker J. Premature ovarian failure: a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy. Hum Reprod Update 1999; 5:483-492. (Pubitemid 29512134)
36. Miller VM, Manson JE. Women's Health Initiative Hormone Therapy Trials: new insights on cardiovascular disease from additional years of follow up. Curr Cardiovasc Risk Rep 2013; 7:196-202.
37. Appelbaum H. Introduction: should ovarian failure in survivors of childhood cancers be treated with hormonal therapy? J Pediatr Adolesc Gynecol 2011; 24:98.
38. Fish JD. Part 1. Hormone replacement for survivors of childhood cancer with ovarian failure -when is it worth the risk? J Pediatr Adolesc Gynecol 2011; 24:98-101.
39. Pantelis T, Nikolaos V, Zoe I, Efthymios D. Long-term followup of adolescent and young adult females with hypergonadotropic hypogonadism. Int J Endocrinol 2012; 2012:862-892.
40. Ross JL, Quigley CA, Cao D, et al. Growth hormone plus childhood low-dose estrogen in Turner's syndrome. N Engl J Med 2011; 364:1230-1242.
41. Wasserman D, Asch A. Reproductive medicine and Turner syndrome: ethical issues. Fertil Steril 2012; 98:792-796.
42. Kim NY, Lee DY, Kim MJ, et al. Estrogen requirements in girls with Turner syndrome; how low is enough for initiating puberty and uterine development? Gynecol Endocrinol 2012; 28:130-133. This is the first study to specifically address the minimal estrogen requirement for initiating puberty and optimal uterine development in adolescents with Turner syndrome.
43. Johnson RH, Kroon L. Optimizing fertility preservation practices for adolescent and young adult cancer patients. J Natl Compr Canc Netw 2013; 11:71-77. This publication from the National Comprehensive Cancer Network reviews the guidelines from major professional organizations regarding fertility preservation for adolescents and young adults with cancer.
44. Chen H, Li J, Cui T, Hu L. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev 2011; CD008018.
45. Practice Committees of American Society for Reproductive Medicine; Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline. Fertil Steril 2013; 99:37-43. This document outlines the rationale for no longer considering oocyte cryopreservation to be an experimental treatment.
46. Ernst E, Kjaersgaard M, Birkebaek NH, et al. Case report: stimulation of puberty in a girl with chemo-and radiation therapy induced ovarian failure by transplantation of a small part of her frozen/thawed ovarian tissue. Eur J Cancer 2013; 49:911-914. This is the first report that in a girl treated for cancer, transplanted ovarian tissue regains function and secretes estradiol in a sufficient amount to induce puberty.
47. Donnez J, Dolmans MM, Pellicer A, et al. Restoration of ovarian activity and pregnancy after transplantation of cryopreserved ovarian tissue: a review of 60 cases of reimplantation. Fertil Steril 2013; 99:1503-1513. This report summarizes the recent outcomes from transplantation of ovarian tissue.
48. Birgit B, Julius H, Carsten R, et al. Fertility preservation in girls with turner syndrome: prognostic signs of the presence of ovarian follicles. J Clin Endocrinol Metab 2009; 94:74-80.
49. Oktay K, Rodriguez-Wallberg KA, Sahin G. Fertility preservation by ovarian stimulation and oocyte cryopreservation in a 14-year-old adolescent with Turner syndrome mosaicism and impending premature ovarian failure. Fertil Steril 2010; 94:753.e15-753.e19.
50. Reindollar RH. Turner syndrome: contemporary thoughts and reproductive issues. Semin Reprod Med 2011; 29:342-352.